Tech4Good Pitch Contest

Showcasing Korea’s Startup Innovation

As part of KES 2025, the French Tech Seoul, in collaboration with French-Korean Chamber of Commerce and Industry (FKCCI), is proud to organize the Tech for Good Pitch Contest on October 24, 2025, from 1:00 PM to 3:00 PM at COEX, Seoul. 

This dynamic session will spotlight Korean startups pioneering solutions that leverage technology to create positive social, health, and environmental impact. Building on the theme “AI for Good: Scaling Human Impact through Technology, Health & Industry Transformation”, the contest will bring together entrepreneurs, investors, and business leaders to discuss how innovation can shape a more sustainable future. 

Register 

Why Attend? 

• Discover cutting-edge Korean startups driving innovation for social good 

• Connect with investors, corporates, and mentors from France and Korea 

• Explore partnership opportunities across tech, health, and sustainability sectors 

---

Program Highlights 

• Opening by French Tech Seoul 
• Startup Pitches: Selected Korean startups present innovative solutions in AI, health tech, sustainability, and digital transformation 
• Feedback & Q&A from a panel of experts and investors 
• Networking session with founders, partners, and industry leaders 

Register 

 

---

Startups 

Amously Inc. is an AI company specializing in semiconductor manufacturing automation, offering process optimization, virtual metrology, and scalable AI platforms for global fabs.

Krako is a decentralized AI compute network that cuts inference costs by 10× through micro-task distribution across idle devices, already processing 320K+ tasks and generating revenue ahead of its token launch.

WDT Inc. is a care-tech company enhancing communication and automation in elderly care to improve quality of life for families, caregivers, and seniors, starting in Japan with plans to expand across Asia.

E&S Healthcare develops blood-based diagnostic technologies and IVD devices for early, reliable cancer detection, leveraging novel biomarkers and expertise from a national R&D program.

Modalités d'accès